biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat severe, life-threatening diseases. Adult stem cells play a key role in the growth, maintenance and repair of many tissues and organ systems in the body. Due to their natural ability to self-renew, and to regenerate and repair diseased or damaged tissue, adult stem cells hold considerable therapeutic promise. http://fatetherapeutics.com/about-us/
buran
: Our approach utilizes established pharmacologic
modalities, such as small molecules, and targets well-characterized biological mechanisms to program the fate and enhance the therapeutic potential of adult stem cells. Our lead product candidate, PROHEMA®, is an ex vivo programmed hematopoietic cellular therapeutic, which is currently in clinical development for patients undergoing hematopoietic stem cell transplantation for the treatment of hematologic malignancies and certain rare genetic disorders. We are also applying our reprogramming modulators to develop human induced pluripotent stem cell-derived cellular therapeutics, and evaluating the in vivo programming of muscle satellite stem cells using our Wnt7a-based protein analogs for muscle regeneration. http://fatetherapeutics.com/about-us/
Top am Montag, Flop am Dienstag – so lässt sich die bisherige Börsenwoche zusammenfassen. Am Mittag zeigt sich der deutsche Leitindex ohne Schwung. Das Geschehen an den Börsen bestimmt die US-Politik. http://www.ariva.de/news/Dax-ohne-Antrieb-5351487
Thinly traded nano cap Fate Therapeutics (FATE) is ahead 18% premarket on increased volume in response to its announcement that the FDA has designated lead
Thread abonnieren
hihi